STOCK TITAN

Evofem Bioscienc - EVFM STOCK NEWS

Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.

Overview of Evofem Biosciences

Evofem Biosciences (symbol: EVFM) is a pioneering biotechnology company dedicated to transforming women's sexual and reproductive health with innovative, non-hormonal and on-demand solutions. As a key player in the reproductive health and innovative biotechnology space, the company develops and markets products that empower women to control their contraception through non-invasive methods, aligning with a modern lifestyle and core values.

Core Business and Product Portfolio

The cornerstone of Evofem's commercial efforts is its FDA-approved product, a hormone-free, locally-acting contraceptive vaginal gel designed for use on demand. Administered shortly before intercourse, the product works by maintaining the natural pH balance of the vaginal environment, creating conditions that are inhospitable to sperm and select pathogens. This unique mechanism not only helps reduce the risk of unintended pregnancy but also caters to women seeking alternatives to systemic, hormone-based methods.

Innovative Technology and Patent Portfolio

At the heart of Evofem Biosciences is an emphasis on innovation and proprietary technology. The company has secured multiple patents covering both the composition and methods of use for its contraceptive gel. These patents underscore the company's commitment to advancing reproductive health through scientific research and offer a foundation that supports sustained product differentiation in a competitive environment.

Market Position and Global Reach

Evofem stands out in a landscape traditionally dominated by hormonal contraceptives by offering a woman-controlled, non-systemic alternative. The company consistently addresses a fundamental need for effective contraception that aligns with personal preferences and lifestyles. Strategic partnerships with telemedicine providers and international entities have broadened its reach, providing access to diverse global markets and reinforcing its market position as a specialist in women's health innovations.

Strategic Alliances and Commercial Partnerships

The company actively forges partnerships designed to enhance product accessibility and market penetration. Collaborations with telehealth platforms cater to the increasing demand for convenient healthcare services, while agreements in key regions expand Evofem's global footprint. These business development initiatives underline the company's strategic effort to diversify revenue streams and extend its impact in addressing the unmet needs of women around the world.

Commitment to Research and Quality

Evofem Biosciences invests heavily in research and quality assurance, ensuring that its products adhere to the highest standards of safety and efficacy. Its extensive clinical research and robust regulatory filings highlight a rigorous development process that supports both patient safety and product innovation. The company's dedication to meeting stringent regulatory requirements is a testament to its commitment to advanced healthcare solutions and its credibility within the biotechnology industry.

Industry Impact and Future Context

While the company does not predict future performance, its strategic emphasis on innovative, non-hormonal contraception has already carved out a niche within the competitive landscape of women's health. Investment in technology, coupled with a diversified product strategy that now includes therapeutic agents for sexual health infections, positions Evofem as a comprehensive provider addressing multiple aspects of women's reproductive health needs. This comprehensive approach not only enhances the overall value proposition but also exemplifies the company's forward-thinking philosophy in meeting both current and emerging demands.

Conclusion

Evofem Biosciences maintains a strong, evidence-based position in the biotechnology sector, firmly rooted in its dedication to improving women's health through innovative, non-hormonal, and on-demand therapies. For investors and analysts, the company offers a complex yet coherent business model characterized by robust research, strategic partnerships, and a dynamic approach to addressing the unique needs of women across global markets.

Rhea-AI Summary

Evofem Biosciences (OTCQB: EVFM) has entered into a License and Supply Agreement with Windtree Therapeutics (NasdaqCM: WINT) to reduce manufacturing costs of PHEXXI, their FDA-approved hormone-free contraceptive vaginal gel. The partnership is expected to decrease PHEXXI's manufacturing costs by 55% to 60% from current levels, with no tech transfer costs to Evofem.

PHEXXI, which prevents pregnancy by maintaining normal vaginal pH levels inhospitable to sperm, will benefit from Windtree's manufacturing contacts to achieve lower production costs. This cost reduction aims to facilitate PHEXXI's global expansion into price-sensitive markets where non-hormonal contraceptives are in demand.

Evofem maintains ownership and continues U.S. commercialization through its sales team, while pursuing international expansion through strategic partnerships, including a July 2024 license agreement with Pharma 1 Drug Store for UAE market entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
none
-
Rhea-AI Summary

Evofem Biosciences (OTCQB: EVFM) reported its financial results for Q4 and full-year 2024, marking its fourth consecutive year of net sales growth. The company achieved $19.4 million in net sales for 2024, a 6% increase from 2023, primarily driven by PHEXXI® sales and improved gross-to-net ratio.

Key operational highlights include:

  • Total operating expense reduced by 27% to $26.4 million (excluding SOLOSEC amortization)
  • Sales and marketing expense at 47% of net sales for 2024, the best ratio since PHEXXI's launch
  • Loss from operations improved by 57% to $7.7 million
  • Revenue stream diversified through SOLOSEC® acquisition in July 2024

The company entered a fifth amendment to the merger agreement with Aditxt (NASDAQ: ADTX), requiring $1.5 million funding by April 7, 2025, and merger consummation by September 30, 2025. Additionally, Evofem partnered with Windtree Therapeutics to reduce PHEXXI manufacturing costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Summary

Evofem Biosciences (OTCQB: EVFM) has received a Notice of Allowance from the USPTO for a new patent application related to SOLOSEC®, extending its intellectual property protection until 2040. The patent covers the treatment of trichomoniasis with SOLOSEC® 2g oral granules, focusing on pharmacokinetics and formulation features.

SOLOSEC® is the first and only single-dose oral antibiotic FDA-approved for treating both bacterial vaginosis in females and trichomoniasis in people 12 years and older. The company acquired global rights to the product in July 2024 and relaunched it in the U.S. in November 2024.

The patent extension provides an additional five years of protection beyond the previous 2035 expiration. Trichomoniasis, affecting an estimated 6.9 million new cases annually in the U.S., is the most common non-viral sexually transmitted infection globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
Rhea-AI Summary

Evofem Biosciences (EVFM) reported Q3 2024 financial results, highlighting a 31% improvement in operating loss to $2.4 million compared to $3.6 million in Q3 2023. Net product sales decreased 12% to $4.5 million. The company acquired global rights to SOLOSEC, a single-dose oral antibiotic, and licensed Phexxi commercial rights in the Middle East. Total operating expenses decreased 20% to $6.9 million. Aditxt invested $5.0 million in Evofem since May 2024, including $1.3 million in Q3 and $2.7 million in October 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
-
Rhea-AI Summary

Evofem Biosciences (OTCQB: EVFM) has secured voting agreements with Series E-1 stockholders and convertible noteholders to support its proposed merger with Aditxt's subsidiary Adifem. This follows Aditxt's recent $2.28 million investment in Evofem through Series F-1 convertible preferred stock, completing their total $5.0 million commitment since May 2024. The merger's closing conditions include majority shareholder approval and Aditxt raising approximately $17 million, with $15.2 million needed to satisfy Evofem's senior secured noteholder. The capital received has enabled Evofem to acquire SOLOSEC® and support Phexxi® initiatives targeting GLP-1 users.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Aditxt (NASDAQ: ADTX) has announced a virtual fireside chat on October 28, 2024, at 11:30 AM ET, featuring Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier, and moderated by Dr. Drew Pinsky. The event will focus on:

  • Aditxt's acquisition of Evofem
  • Post-acquisition plans for Evofem
  • Aditxt's approach to accelerating innovations

The chat will highlight Evofem's evolution into a multi-product women's health franchise, including the re-launch of Solosec® and the planned launch of the Mitomic Endometriosis Test (MET™) in mid-2025. Aditxt estimates it will require $19.3 million to fund the Evofem acquisition, including $1.8 million for merger consideration and $2.28 million for additional Evofem stock purchase by October 31, 2024. An additional $15.2 million is needed to satisfy Evofem's Senior Secured Note at closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 million by October 31, 2024.

Evofem has expanded from a single-product company to offering diversified solutions in women's health, including Phexxi (contraceptive gel) and SOLOSEC (antibiotic). They are preparing to launch the Mitomic Endometriosis Test in mid-2025 and have signed a licensing agreement with Pharma 1 Drug Store to bring Phexxi to the Gulf Cooperation Council region.

Aditxt aims to accelerate innovative health companies through its business platform, which includes subsidiaries Adimune (immune health) and Pearsanta (precision health). Both companies believe the merger will strengthen Evofem's ability to expand access to women's health products globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
-
Rhea-AI Summary

Aditxt, Inc. (NASDAQ: ADTX) announced that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has filed a preliminary proxy to seek stockholder approval for the merger outlined in the Amended and Restated Merger Agreement dated July 12, 2024. The agreement involves Adifem, Inc., a wholly-owned subsidiary of Aditxt, merging with Evofem, resulting in Evofem becoming a wholly-owned subsidiary of Aditxt.

The companies are targeting to close the transaction in the fourth quarter of 2024, subject to Evofem stockholder approval and other closing conditions, including Aditxt raising sufficient capital to fund its obligations at closing. However, no assurance is provided that all conditions will be met or that the transaction will ultimately close.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
-
Rhea-AI Summary

Aditxt, Inc. (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has entered into a collaboration agreement with Evofem Biosciences for the U.S. launch of a blood-based diagnostic test for endometriosis in mid-2025. The Mitomic® Endometriosis Test (MET™) detects a specific deletion in mitochondrial DNA, a novel biomarker for endometriosis.

Endometriosis affects approximately 190 million women worldwide, with no current validated blood-based tests available. The collaboration aims to develop a go-to-market strategy and commercial plan for MET. Over 300 endometriosis cases have been evaluated using MET, with 600 planned for clinical validation.

This partnership aligns with Evofem's strategy to expand its women's health product offerings and Aditxt's goal of accelerating healthcare innovations. The collaboration may also lead to future tests, such as early detection of ovarian cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
Rhea-AI Summary

Aditxt (NASDAQ: ADTX) and Evofem Biosciences (OTCQB: EVFM) have signed a Second Amendment to their merger agreement, extending the timeline for Aditxt's $3 million funding to Evofem. The acquisition is now targeted to close in Q4 2024. Evofem aims to grow revenue through its three-pronged strategy: increasing U.S. sales of Phexxi® and SOLOSEC®, expanding its portfolio, and pursuing international partnerships. Aditxt plans to introduce four health-focused programs, including women's health through the Evofem merger. The deal's completion depends on shareholder approvals and Aditxt securing sufficient capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.28%
Tags

FAQ

What is the current stock price of Evofem Bioscienc (EVFM)?

The current stock price of Evofem Bioscienc (EVFM) is $0.0094 as of April 1, 2025.

What is the market cap of Evofem Bioscienc (EVFM)?

The market cap of Evofem Bioscienc (EVFM) is approximately 832.7K.

What does Evofem Biosciences specialize in?

Evofem Biosciences specializes in developing innovative, non-hormonal, on-demand products for women’s sexual and reproductive health, primarily focusing on contraception.

How does the company's primary product work?

The company's flagship product is a locally-acting contraceptive vaginal gel that maintains the natural pH of the vagina, creating an environment that is inhospitable to sperm and certain pathogens, thereby preventing pregnancy without systemic hormones.

What makes Evofem's approach unique in the contraceptive market?

Evofem's approach is unique because it offers a woman-controlled, non-invasive, and rapidly reversible contraceptive method, unlike traditional hormone-based products, aligning with modern lifestyle preferences.

How does Evofem generate revenue?

Revenue is primarily generated through the commercialization of its FDA-approved products, strategic partnerships, licensing agreements, and maintaining a robust patent portfolio that supports product differentiation.

What role do patents play in Evofem's business model?

Patents are critical to Evofem’s business model as they protect its innovative formulations and methods, ensuring exclusivity and supporting long-term competitive advantages in the market.

How does Evofem expand its market reach?

The company expands its market reach through strategic alliances with telemedicine platforms, international commercialization agreements, and partnerships that facilitate access to diverse global markets.

How does Evofem ensure product quality and safety?

Evofem commits significant resources to research and quality assurance, adhering to extensive clinical trials and regulatory approvals to maintain high safety and efficacy standards for all its products.

What is the significance of non-hormonal contraception for women?

Non-hormonal contraception offers an alternative for women who prefer to avoid systemic hormones due to health concerns or lifestyle preferences, providing a safer and on-demand option that aligns with personal health values.
Evofem Bioscienc

OTC:EVFM

EVFM Rankings

EVFM Stock Data

832.73k
113.35M
0%
0.1%
10.98%
Biotechnology
Healthcare
Link
United States
San Diego